| __timestamp | Summit Therapeutics Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 6795238 | 612613000000 |
| Thursday, January 1, 2015 | 7454247 | 650773000000 |
| Friday, January 1, 2016 | 10345862 | 619061000000 |
| Sunday, January 1, 2017 | 16984203 | 628106000000 |
| Monday, January 1, 2018 | 16187290 | 717599000000 |
| Tuesday, January 1, 2019 | 9299233.54 | 964737000000 |
| Wednesday, January 1, 2020 | 19232000 | 875663000000 |
| Friday, January 1, 2021 | 23611000 | 886361000000 |
| Saturday, January 1, 2022 | 26700000 | 997309000000 |
| Sunday, January 1, 2023 | 28215000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Summit Therapeutics Inc. from 2014 to 2023. Takeda, a global leader, consistently shows SG&A expenses in the hundreds of billions, peaking at approximately $1.05 trillion in 2023. In contrast, Summit Therapeutics, a smaller player, exhibits a steady increase, with expenses rising from $6.8 million in 2014 to $28.2 million in 2023, marking a 315% increase over the decade.
This stark contrast highlights the scale and operational differences between the two companies. While Takeda's expenses reflect its expansive global operations, Summit's growth trajectory suggests strategic investments in its niche markets. Notably, data for 2024 is incomplete, indicating potential shifts in future trends. This financial snapshot offers valuable insights into the strategic priorities and market positioning of these pharmaceutical giants.
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Summit Therapeutics Inc.
SG&A Efficiency Analysis: Comparing GSK plc and Summit Therapeutics Inc.
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and argenx SE
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs BeiGene, Ltd. Trends and Insights
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Halozyme Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Veracyte, Inc. Trends and Insights
Takeda Pharmaceutical Company Limited vs Vericel Corporation: SG&A Expense Trends
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Celldex Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Amneal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Summit Therapeutics Inc. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Viridian Therapeutics, Inc.